JP2021532063A5 - - Google Patents
Info
- Publication number
- JP2021532063A5 JP2021532063A5 JP2020567044A JP2020567044A JP2021532063A5 JP 2021532063 A5 JP2021532063 A5 JP 2021532063A5 JP 2020567044 A JP2020567044 A JP 2020567044A JP 2020567044 A JP2020567044 A JP 2020567044A JP 2021532063 A5 JP2021532063 A5 JP 2021532063A5
- Authority
- JP
- Japan
- Prior art keywords
- groups
- alkyl
- antibody
- cancer
- hydrogen
- Prior art date
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023196433A JP7753317B2 (ja) | 2018-06-01 | 2023-11-20 | スプライシング調節薬抗体－薬物コンジュゲート及びその使用方法 |
| JP2025165244A JP2026004432A (ja) | 2018-06-01 | 2025-10-01 | スプライシング調節薬抗体－薬物コンジュゲート及びその使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862679672P | 2018-06-01 | 2018-06-01 | |
| US201862679631P | 2018-06-01 | 2018-06-01 | |
| US62/679,631 | 2018-06-01 | ||
| US62/679,672 | 2018-06-01 | ||
| US201862779324P | 2018-12-13 | 2018-12-13 | |
| US62/779,324 | 2018-12-13 | ||
| PCT/US2019/035015 WO2019232449A1 (en) | 2018-06-01 | 2019-05-31 | Splicing modulator antibody-drug conjugates and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023196433A Division JP7753317B2 (ja) | 2018-06-01 | 2023-11-20 | スプライシング調節薬抗体－薬物コンジュゲート及びその使用方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021532063A JP2021532063A (ja) | 2021-11-25 |
| JP2021532063A5 true JP2021532063A5 (https=) | 2022-06-06 |
| JPWO2019232449A5 JPWO2019232449A5 (https=) | 2022-06-06 |
| JP7390315B2 JP7390315B2 (ja) | 2023-12-01 |
Family
ID=66999916
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567044A Active JP7390315B2 (ja) | 2018-06-01 | 2019-05-31 | スプライシング調節薬抗体－薬物コンジュゲート及びその使用方法 |
| JP2023196433A Active JP7753317B2 (ja) | 2018-06-01 | 2023-11-20 | スプライシング調節薬抗体－薬物コンジュゲート及びその使用方法 |
| JP2025165244A Pending JP2026004432A (ja) | 2018-06-01 | 2025-10-01 | スプライシング調節薬抗体－薬物コンジュゲート及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023196433A Active JP7753317B2 (ja) | 2018-06-01 | 2023-11-20 | スプライシング調節薬抗体－薬物コンジュゲート及びその使用方法 |
| JP2025165244A Pending JP2026004432A (ja) | 2018-06-01 | 2025-10-01 | スプライシング調節薬抗体－薬物コンジュゲート及びその使用方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US12172986B2 (https=) |
| EP (1) | EP3801632A1 (https=) |
| JP (3) | JP7390315B2 (https=) |
| KR (1) | KR20210016375A (https=) |
| CN (5) | CN112218663B (https=) |
| AU (1) | AU2019277700B2 (https=) |
| BR (1) | BR112020024549A2 (https=) |
| CA (1) | CA3099920A1 (https=) |
| CL (8) | CL2020003117A1 (https=) |
| CO (1) | CO2020016137A2 (https=) |
| IL (3) | IL279062B2 (https=) |
| JO (3) | JOP20200268A1 (https=) |
| MX (1) | MX2020012997A (https=) |
| PE (1) | PE20211220A1 (https=) |
| PH (1) | PH12020500672A1 (https=) |
| SG (1) | SG11202010341PA (https=) |
| TW (2) | TW202015739A (https=) |
| WO (1) | WO2019232449A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020003783A (es) | 2017-10-02 | 2021-01-08 | Visterra Inc | Moleculas de anticuerpo de cd138 y sus usos. |
| MX2020012940A (es) | 2018-06-01 | 2021-03-25 | Eisai R&D Man Co Ltd | Metodos de uso de moduladores de empalme. |
| JOP20200268A1 (ar) | 2018-06-01 | 2020-10-26 | Eisai R&D Man Co Ltd | تضفير مترافقات عقار جسم مضاد معدل وطرق استخدامها |
| PE20211473A1 (es) * | 2018-12-13 | 2021-08-05 | Eisai Randd Man Co Ltd | Conjugados de anticuerpo-farmaco de herboxidieno y metodos de uso |
| US20220098578A1 (en) | 2019-01-31 | 2022-03-31 | Bar Ilan University | Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy |
| GB201905780D0 (en) * | 2019-04-25 | 2019-06-05 | La Thangue Nicholas | Cancer therapy |
| CA3142021A1 (en) | 2019-06-17 | 2020-12-24 | Visterra, Inc. | Humanized antibody molecules to cd138 and uses thereof |
| JP7657213B2 (ja) | 2019-11-07 | 2025-04-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗メソテリンエリブリン抗体－薬物コンジュゲート及び使用方法 |
| US20230074385A1 (en) * | 2019-12-23 | 2023-03-09 | Eisai R&D Management Co., Ltd. | Method for producing eribulin-based antibody-drug conjugate |
| BR112022019532A2 (pt) * | 2020-03-31 | 2022-12-06 | Orum Therapeutics Inc | Conjugados de neodegrader |
| AR122546A1 (es) * | 2020-06-05 | 2022-09-21 | Eisai R&D Man Co Ltd | Conjugados de anticuerpo anti bcma-fármaco y métodos de uso |
| KR20230104204A (ko) | 2020-11-04 | 2023-07-07 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 골수이형성 증후군(mds)에 대한 바이오마커 및 이를 사용하는 방법 |
| IL308486A (en) * | 2021-05-21 | 2024-01-01 | Remegen Co Ltd | Use of an antibody-drug conjugate in combination with an immune checkpoint inhibitor in the treatment of urothelial cancer |
| WO2023097254A1 (en) * | 2021-11-24 | 2023-06-01 | Visterra, Inc. | Engineered antibody molecules to cd138 and uses thereof |
| WO2023131866A1 (en) | 2022-01-05 | 2023-07-13 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
| CN114573698B (zh) * | 2022-03-16 | 2023-01-06 | 沈阳三生制药有限责任公司 | 一种FcRn抗原结合蛋白及其制备方法和应用 |
| CN115974976B (zh) * | 2022-11-23 | 2024-06-04 | 华中科技大学 | 拮抗多肽及用于制备抗急性肾损伤药物的应用 |
| AR132368A1 (es) | 2023-04-18 | 2025-06-18 | Astrazeneca Ab | Conjugados que comprenden enlazadores escindibles |
| WO2025078841A2 (en) | 2023-10-11 | 2025-04-17 | Antikor Biopharma Limited | Antibodies, conjugates, and uses thereof |
| WO2025132978A1 (en) * | 2023-12-19 | 2025-06-26 | BioNTech SE | Cfc1 binding molecule |
| WO2025132976A1 (en) * | 2023-12-19 | 2025-06-26 | BioNTech SE | Cfc1 binding molecule |
| WO2025240362A1 (en) * | 2024-05-13 | 2025-11-20 | The Board Of Trustees Of The Leland Stanford Junior University | Discovery of enpp3 as a cgamp hydrolase with a role in anti-cancer immunity |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| WO1992019244A2 (en) | 1991-05-01 | 1992-11-12 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | A method for treating infectious respiratory diseases |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| NZ322175A (en) | 1995-11-10 | 1999-02-25 | Elan Corp Plc | Peptides which enhance transport across tissues and methods of identifying the same |
| ATE234635T1 (de) | 1995-12-22 | 2003-04-15 | Bristol Myers Squibb Co | Verzweigte hydrazongruppen enthaltende kuppler |
| DK0885002T3 (da) | 1996-03-04 | 2011-08-22 | Penn State Res Found | Materialer og fremgangsmåder til forøgelse af cellulær internalisering |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| DE69732306T2 (de) | 1997-01-16 | 2006-01-12 | Massachusetts Institute Of Technology, Cambridge | Zubereitung von partikelhaltigen arzneimitteln zur inhalation |
| CA2336139C (en) | 1998-06-24 | 2008-10-14 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| US7555503B1 (en) | 2000-06-30 | 2009-06-30 | Click Commerce, Inc. | Method and apparatus for managing updates to a catalog |
| TWI311558B (en) | 2001-02-01 | 2009-07-01 | Mercian Corporatio | Novel physiologically active substance |
| PT1390389E (pt) | 2001-04-26 | 2009-04-03 | Biogen Idec Inc | Anticorpos que bloqueiam o cripto e as utilizações dos mesmos |
| TWI334866B (en) | 2002-05-29 | 2010-12-21 | Mercian Corp | Novel physiologically active substances |
| JP4459051B2 (ja) | 2002-07-31 | 2010-04-28 | メルシャン株式会社 | 新規生理活性物質 |
| RU2338741C2 (ru) | 2002-07-31 | 2008-11-20 | Мершан Корпорейшн | Новые физиологически активные вещества |
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| WO2005075681A1 (ja) | 2004-02-06 | 2005-08-18 | Eisai R & D Management Co., Ltd. | 抗癌剤に対する癌細胞の感受性を検定する方法 |
| CA2556027C (en) | 2004-02-12 | 2015-11-24 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
| KR20120064120A (ko) | 2004-06-01 | 2012-06-18 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| EP1817059A2 (en) | 2004-12-01 | 2007-08-15 | Genentech, Inc. | Conjugates of 1,8-bis-naphthalimides with an antibody |
| US20090304721A1 (en) | 2005-09-07 | 2009-12-10 | Medlmmune, Inc | Toxin conjugated eph receptor antibodies |
| CN101282967B (zh) | 2005-10-13 | 2011-01-26 | 卫材R&D管理有限公司 | 普拉二烯内酯b和普拉二烯内酯d的全合成 |
| JPWO2008016187A1 (ja) | 2006-08-02 | 2009-12-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | プラジエノライド類のターゲット分子、本ターゲット分子に結合する化合物、及びそのスクリーニング方法 |
| KR20140116546A (ko) | 2006-10-27 | 2014-10-02 | 제넨테크, 인크. | 항체 및 면역접합체 및 이들의 용도 |
| US7790887B2 (en) | 2007-01-29 | 2010-09-07 | Eisai R&D Management Co., Ltd. | Macrolide compound in solid form, process for preparation thereof, and pharmaceutical composition containing the same |
| WO2008111464A1 (ja) | 2007-03-05 | 2008-09-18 | Eisai R & D Management Co., Ltd. | スプライシング異常を指標とする抗ガン剤の作用検定方法 |
| WO2009008492A1 (ja) | 2007-07-06 | 2009-01-15 | Eisai R & D Management Co., Ltd. | マクロライド系化合物の製造方法およびその製造中間体 |
| WO2010121226A2 (en) | 2009-04-17 | 2010-10-21 | The Regents Of The University Of California | Anticancer agents |
| JPWO2011074621A1 (ja) | 2009-12-18 | 2013-04-25 | 株式会社医学生物学研究所 | メソセリン（ｍｓｌｎ）に対する抗体及びその用途 |
| AU2013256596A1 (en) | 2012-05-01 | 2014-10-09 | Genentech, Inc. | Anti-PMEL17 antibodies and immunoconjugates |
| US9981046B2 (en) | 2012-05-15 | 2018-05-29 | Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. | Drug-conjugates, conjugation methods, and uses thereof |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| US20140069822A1 (en) | 2012-09-10 | 2014-03-13 | Antec Leyden B.V. | Electrochemical reduction of disulfide bonds in proteinaceous substances and electrochemical cell for carrying out such reduction |
| US9155357B2 (en) | 2012-09-11 | 2015-10-13 | Nike, Inc. | Automated strobel printing |
| MX340090B (es) * | 2012-11-05 | 2016-06-23 | Pfizer | Analogos de spliceostatina. |
| US20140275010A1 (en) | 2013-03-12 | 2014-09-18 | Guo Zhu Zheng | Quaternary salts |
| US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
| JP6744212B2 (ja) * | 2013-06-21 | 2020-08-19 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | ポリペプチドの酵素的結合 |
| EP3027224B1 (en) | 2013-07-31 | 2020-06-03 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates using transglutaminase |
| PE20160671A1 (es) | 2013-08-02 | 2016-07-09 | Pfizer | Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco |
| US20150125386A1 (en) | 2013-11-05 | 2015-05-07 | Immunomedics, Inc. | Humanized anti-ceacam5 antibody and uses thereof |
| SI3466976T1 (sl) | 2014-01-31 | 2021-12-31 | Daiichi Sankyo Company, Limited | Anti-her2 konjugat protitelesa-zdravila |
| SI3134127T1 (sl) | 2014-04-25 | 2020-06-30 | Rinat Neuroscience Corp. | Konjugati zdravil s protitelesi z visoko stopnjo zdravila |
| UA119458C2 (uk) | 2014-05-15 | 2019-06-25 | Ейсей Р Енд Д Менеджмент Ко., Лтд. | Сполуки піридину пладієноліду та способи застосування |
| JP6349171B2 (ja) | 2014-07-07 | 2018-06-27 | ローム株式会社 | ノイズ除去回路、タイミングコントローラ、ディスプレイ装置、電子機器、ソースドライバの制御方法 |
| ES2916923T3 (es) | 2014-07-11 | 2022-07-06 | Ventana Med Syst Inc | Anticuerpos anti-PD-L1 y usos diagnósticos de los mismos |
| ES2797754T3 (es) | 2014-08-28 | 2020-12-03 | Pfizer | Enlazadores moduladores de la estabilidad para su uso con conjugados de fármaco y anticuerpo |
| AU2016206475B2 (en) | 2015-01-16 | 2021-11-04 | City Of Hope | Cell penetrating antibodies |
| PL3988117T3 (pl) | 2015-04-13 | 2025-03-10 | Pfizer Inc. | Przeciwciała terapeutyczne i ich zastosowania |
| HK1255234A1 (zh) * | 2015-07-16 | 2019-08-09 | 塞勒兰特治疗公司 | 经半胱氨酸取代的免疫球蛋白 |
| ES2887201T3 (es) | 2015-09-01 | 2021-12-22 | Eisai R&D Man Co Ltd | Variantes de empalme asociadas con mutantes neomórficos de SF3B1 |
| SG11201803519YA (en) | 2015-11-18 | 2018-06-28 | Eisai R&D Man Co Ltd | A solid state form of pladienolide pyridine compounds and methods of use |
| US10689458B2 (en) | 2015-11-30 | 2020-06-23 | Pfizer Inc. | Site specific HER2 antibody drug conjugates |
| US10221242B2 (en) | 2016-01-21 | 2019-03-05 | Pfizer Inc. | Antibodies specific for epidermal growth factor receptor variant III and their uses |
| EP3423105B1 (en) | 2016-03-02 | 2021-05-05 | Eisai R&D Management Co., Ltd. | Eribulin-based antibody-drug conjugates and methods of use |
| CN105669800B (zh) | 2016-03-03 | 2017-12-15 | 湖南省农产品加工研究所 | 一种从柑橘中联合提取精油、果胶、橙皮苷、辛弗林和柠檬苦素的方法 |
| WO2017212250A1 (en) | 2016-06-06 | 2017-12-14 | Polytherics Limited | Antibodies, uses thereof and conjugates thereof |
| CA3042442C (en) | 2016-11-14 | 2024-01-02 | Hangzhou Dac Biotech Co., Ltd | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses of such conjugates with the linkers |
| WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
| GB201711068D0 (en) | 2017-07-10 | 2017-08-23 | Crescendo Biologics Ltd | Therapeutic molecules binding PSMA |
| WO2019075472A1 (en) | 2017-10-13 | 2019-04-18 | A&G Pharmaceutical, Inc. | MONOCLONAL AND CONJUGATED ANTIBODIES AGAINST THE PROSTAGLANDIN F2 RECEPTOR INHIBITOR AND USES THEREOF |
| WO2019199667A2 (en) | 2018-04-09 | 2019-10-17 | Keaney Gregg F | Certain pladienolide compounds and methods of use |
| PE20212329A1 (es) | 2018-04-12 | 2021-12-14 | Eisai Randd Man Co Ltd | Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cancer |
| JOP20200268A1 (ar) | 2018-06-01 | 2020-10-26 | Eisai R&D Man Co Ltd | تضفير مترافقات عقار جسم مضاد معدل وطرق استخدامها |
| MX2020012940A (es) | 2018-06-01 | 2021-03-25 | Eisai R&D Man Co Ltd | Metodos de uso de moduladores de empalme. |
| PE20211473A1 (es) | 2018-12-13 | 2021-08-05 | Eisai Randd Man Co Ltd | Conjugados de anticuerpo-farmaco de herboxidieno y metodos de uso |
| JP7657213B2 (ja) | 2019-11-07 | 2025-04-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗メソテリンエリブリン抗体－薬物コンジュゲート及び使用方法 |
| CN118949063A (zh) | 2020-01-22 | 2024-11-15 | 上海森辉医药有限公司 | 艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用 |
| AR122546A1 (es) | 2020-06-05 | 2022-09-21 | Eisai R&D Man Co Ltd | Conjugados de anticuerpo anti bcma-fármaco y métodos de uso |
-
2019
- 2019-05-31 JO JOP/2020/0268A patent/JOP20200268A1/ar unknown
- 2019-05-31 EP EP19732510.3A patent/EP3801632A1/en active Pending
- 2019-05-31 IL IL279062A patent/IL279062B2/en unknown
- 2019-05-31 AU AU2019277700A patent/AU2019277700B2/en active Active
- 2019-05-31 US US17/059,635 patent/US12172986B2/en active Active
- 2019-05-31 SG SG11202010341PA patent/SG11202010341PA/en unknown
- 2019-05-31 CN CN201980036786.3A patent/CN112218663B/zh active Active
- 2019-05-31 CA CA3099920A patent/CA3099920A1/en active Pending
- 2019-05-31 BR BR112020024549-6A patent/BR112020024549A2/pt unknown
- 2019-05-31 MX MX2020012997A patent/MX2020012997A/es unknown
- 2019-05-31 CN CN202411513187.5A patent/CN119405832A/zh active Pending
- 2019-05-31 IL IL316090A patent/IL316090A/en unknown
- 2019-05-31 TW TW108118955A patent/TW202015739A/zh unknown
- 2019-05-31 PE PE2020001954A patent/PE20211220A1/es unknown
- 2019-05-31 CN CN202411513294.8A patent/CN119405834A/zh active Pending
- 2019-05-31 JP JP2020567044A patent/JP7390315B2/ja active Active
- 2019-05-31 CN CN202411513264.7A patent/CN119405833A/zh active Pending
- 2019-05-31 IL IL305431A patent/IL305431B2/en unknown
- 2019-05-31 TW TW114103019A patent/TW202519520A/zh unknown
- 2019-05-31 KR KR1020207035785A patent/KR20210016375A/ko not_active Ceased
- 2019-05-31 WO PCT/US2019/035015 patent/WO2019232449A1/en not_active Ceased
- 2019-05-31 CN CN202411513167.8A patent/CN119405831A/zh active Pending
-
2020
- 2020-11-26 PH PH12020500672A patent/PH12020500672A1/en unknown
- 2020-11-30 CL CL2020003117A patent/CL2020003117A1/es unknown
- 2020-11-30 US US17/247,117 patent/US11352348B2/en active Active
- 2020-12-22 CO CONC2020/0016137A patent/CO2020016137A2/es unknown
-
2021
- 2021-09-10 CL CL2021002377A patent/CL2021002377A1/es unknown
- 2021-09-10 CL CL2021002378A patent/CL2021002378A1/es unknown
-
2022
- 2022-05-03 US US17/661,909 patent/US11945807B2/en active Active
-
2023
- 2023-05-31 JO JOJO/P/2023/0124A patent/JOP20230124A1/ar unknown
- 2023-05-31 JO JOJO/P/2023/0123A patent/JOP20230123A1/ar unknown
- 2023-11-20 JP JP2023196433A patent/JP7753317B2/ja active Active
-
2024
- 2024-02-19 US US18/581,307 patent/US12514926B2/en active Active
- 2024-04-19 CL CL2024001239A patent/CL2024001239A1/es unknown
- 2024-04-19 CL CL2024001241A patent/CL2024001241A1/es unknown
- 2024-04-19 CL CL2024001243A patent/CL2024001243A1/es unknown
- 2024-04-19 CL CL2024001242A patent/CL2024001242A1/es unknown
- 2024-04-19 CL CL2024001240A patent/CL2024001240A1/es unknown
- 2024-09-10 US US18/830,446 patent/US20250135017A1/en active Pending
-
2025
- 2025-10-01 JP JP2025165244A patent/JP2026004432A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021532063A5 (https=) | ||
| JPWO2019232449A5 (https=) | ||
| JP5925684B2 (ja) | 抗ｇｃｃ分子と関連組成物および方法 | |
| CN108026123B (zh) | 用于偶联的亲水链接体 | |
| RU2685728C2 (ru) | Конъюгат лиганд - цитотоксическое лекарственное средство, способ его получения и его применения | |
| ES2874306T3 (es) | Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12 | |
| KR102023496B1 (ko) | 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도 | |
| ES2818575T3 (es) | Reducción selectiva de anticuerpos con modificación de cisteínas | |
| ES2795818T3 (es) | Anticuerpos CD48 y conjugados de los mismos | |
| CN106414465B (zh) | 带电荷链接体及其在共轭反应上的应用 | |
| RU2018134331A (ru) | Конъюгаты антитело-лекарственное средство на основе эрибулина и способы применения | |
| RU2018119296A (ru) | Конъюгаты антитела, содержащие агонисты толл-подобного рецептора | |
| JP7570329B2 (ja) | ハーボキシジエンスプライシング調節薬抗体－薬物コンジュゲート及びその使用方法 | |
| JP2012522512A5 (https=) | ||
| RU2014148162A (ru) | Анти-pmel17 антитела и их иммуноконъюгаты | |
| JP2018537975A5 (https=) | ||
| TW201905000A (zh) | 含有抗globo h抗體之抗體－藥物共軛物及其用途 | |
| JPWO2023046202A5 (https=) | ||
| CN113453724B (zh) | 基于磺酰基马来酰亚胺的连接子和相应的偶联物 | |
| JPWO2020123836A5 (https=) | ||
| JPWO2021090062A5 (https=) | ||
| JPWO2023033129A5 (https=) | ||
| JP2016511257A (ja) | 癌の治療における抗ｇｃｃ抗体−薬物複合体及びｄｎａ損傷剤の投与 | |
| NZ771328B2 (en) | Splicing modulator antibody-drug conjugates and methods of use | |
| RU2024115226A (ru) | Конъюгаты антитела и лекарственного средства, содержащие модулятор сплайсинга на основе гербоксидиена, и способы их применения |